The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strauss, L.
Right arrow Articles by Zippelius, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Strauss, L.
Right arrow Articles by Zippelius, A.
The Journal of Immunology, 2007, 178: 320-329.
Copyright © 2007 by The American Association of Immunologists, Inc.

Selective Survival of Naturally Occurring Human CD4+CD25+Foxp3+ Regulatory T Cells Cultured with Rapamycin1

Laura Strauss2,*,{dagger}, Theresa L. Whiteside{dagger}, Ashley Knights*, Christoph Bergmann{ddagger}, Alexander Knuth* and Alfred Zippelius2,*

* Medical Oncology, Department of Internal Medicine, University Hospital, Zurich, Switzerland; {dagger} University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213; and {ddagger} Department of Otorhinolaryngology, University Schleswig, Luebeck, Germany

Naturally occurring CD4+CD25+ regulatory T (nTreg) cells are essential for maintaining T cell tolerance to self Ags. We show that discrimination of human Treg from effector CD4+CD25+ non-nTreg cells and their selective survival and proliferation can now be achieved using rapamycin (sirolimus). Human purified CD4+CD25high T cell subsets stimulated via TCR and CD28 or by IL-2 survived and expanded up to 40-fold in the presence of 1 nM rapamycin, while CD4+CD25low or CD4+CD25 T cells did not. The expanding pure populations of CD4+CD25high T cells were resistant to rapamycin-accelerated apoptosis. In contrast, proliferation of CD4+CD25 T cells was blocked by rapamycin, which induced their apoptosis. The rapamycin-expanded CD4+CD25high T cell populations retained a broad TCR repertoire and, like CD4+ CD25+ T cells freshly obtained from the peripheral circulation, constitutively expressed CD25, Foxp3, CD62L, glucocorticoid-induced TNFR family related protein, CTLA-4, and CCR-7. The rapamycin-expanded T cells suppressed proliferation and effector functions of allogeneic or autologous CD4+ and CD8+ T cells in vitro. They equally suppressed Ag-specific and nonspecific responses. Our studies have defined ex vivo conditions for robust expansion of pure populations of human nTreg cells with potent suppressive activity. It is expected that the availability of this otherwise rare T cell subset for further studies will help define the molecular basis of Treg-mediated suppression in humans.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by a Swiss National Science Foundation special program, and a grant from the Cancer Research Institute/Ludwig Institute for Cancer Research Cancer Vaccine Collaborative, the Terry-Fox, Hanne-Liebermann, and Claudia-von-Schilling Foundation, and UBS Wealth Management. A.Z. was supported in part by the Emmy-Noether Program (Zi685-2/3) of the Deutsche Forschungsgemeinschaft. T.L.W. was supported in part by National Institutes of Health Grant PO-1 DE12321.

2 Address correspondence and reprint requests to Dr. Laura Strauss, University of Pittsburgh Cancer Institute, Research Pavilion at the Hillman Cancer Center, 5117 Centre Avenue, Suite 1.27, Pittsburgh, PA 15213-1863; E-mail address: straussl{at}upmc.edu or Dr. Alfred Zippelius, Medical Oncology, Department of Internal Medicine, University Hospital, Raemistrasse 100, 8091, Zurich, Switzerland; E-mail address: Alfred.Zippelius{at}usz.ch

3 Abbreviations used in this paper: Treg, regulatory T; nTreg, naturally occurring CD4+CD25+ Treg; GITR, glucocorticoid-induced TNFR family related protein; TT, tetanus toxoid; ANX V, annexin V; LN, lymph node; MFI, mean fluorescence intensity; PI, propidium iodine.




This article has been cited by other articles:


Home page
J. Immunol.Home page
R. Tao, L. Wang, K. M. Murphy, C. C. Fraser, and W. W. Hancock
Regulatory T Cell Expression of Herpesvirus Entry Mediator Suppresses the Function of B and T Lymphocyte Attenuator-Positive Effector T Cells
J. Immunol., May 15, 2008; 180(10): 6649 - 6655.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
J. Kang, S. J. Huddleston, J. M. Fraser, and A. Khoruts
De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR
J. Leukoc. Biol., May 1, 2008; 83(5): 1230 - 1239.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Basu, T. Golovina, T. Mikheeva, C. H. June, and J. L. Riley
Cutting Edge: Foxp3-Mediated Induction of Pim 2 Allows Human T Regulatory Cells to Preferentially Expand in Rapamycin
J. Immunol., May 1, 2008; 180(9): 5794 - 5798.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
S. Haxhinasto, D. Mathis, and C. Benoist
The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells
J. Exp. Med., March 17, 2008; 205(3): 565 - 574.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Strauss, C. Bergmann, M. J. Szczepanski, S. Lang, J. M. Kirkwood, and T. L. Whiteside
Expression of ICOS on Human Melanoma-Infiltrating CD4+CD25highFoxp3+ T Regulatory Cells: Implications and Impact on Tumor-Mediated Immune Suppression
J. Immunol., March 1, 2008; 180(5): 2967 - 2980.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. J. Ward, A. M. Hall, L. S. Cairns, A. S. Leggat, S. J. Urbaniak, M. A. Vickers, and R. N. Barker
Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia
Blood, January 15, 2008; 111(2): 680 - 687.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Zeiser, D. B. Leveson-Gower, E. A. Zambricki, N. Kambham, A. Beilhack, J. Loh, J.-Z. Hou, and R. S. Negrin
Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells
Blood, January 1, 2008; 111(1): 453 - 462.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Strauss, C. Bergmann, W. Gooding, J. T. Johnson, and T. L. Whiteside
The Frequency and Suppressor Function of CD4+CD25highFoxp3+ T Cells in the Circulation of Patients with Squamous Cell Carcinoma of the Head and Neck
Clin. Cancer Res., November 1, 2007; 13(21): 6301 - 6311.
[Abstract] [Full Text] [PDF]


Home page
Am J Trop Med HygHome page
K. Watanabe, P. N. M. Mwinzi, C. L. Black, E. M. O. Muok, D. M. S. Karanja, W. E. Secor, and D. G. Colley
T Regulatory Cell Levels Decrease in People Infected With Schistosoma mansoni on Effective Treatment
Am J Trop Med Hyg, October 1, 2007; 77(4): 676 - 682.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Bergmann, L. Strauss, R. Zeidler, S. Lang, and T. L. Whiteside
Expansion of Human T Regulatory Type 1 Cells in the Microenvironment of Cyclooxygenase 2 Overexpressing Head and Neck Squamous Cell Carcinoma
Cancer Res., September 15, 2007; 67(18): 8865 - 8873.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Strauss, C. Bergmann, M. Szczepanski, W. Gooding, J. T. Johnson, and T. L. Whiteside
A Unique Subset of CD4+CD25highFoxp3+ T Cells Secreting Interleukin-10 and Transforming Growth Factor-{beta}1 Mediates Suppression in the Tumor Microenvironment
Clin. Cancer Res., August 1, 2007; 13(15): 4345 - 4354.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2007 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2007 by The American Association of Immunologists, Inc. All rights reserved.